Etiology of Parkinson's Disease

There is growing recognition that Parkinson's disease (PD) is likely to arise from the combined effects of genetic predisposition as well as largely unidentified environmental factors. The relative contribution of each varies from one individual to another. Even in situations where more than one family member is affected, the predominant influence may be environmental. Although responsible for only a small minority of cases of PD, recently identified genetic mutations have provided tremendous insights into the basis for neurodegeneration and have led to growing recognition of the importance of abnormal protein handling in Parkinson's as well as other neurodegenerative disorders. Abnormal protein handling may increase susceptibility to oxidative stress; conversely, numerous other factors, including oxidative stress and impaired mitochondrial function can lead to impaired protein degradation. A limited number of environmental factors are known to be toxic to the substantia nigra; in contrast, some factors such as caffeine intake and cigarette smoking may protect against the development of PD, although the mechanisms are not established. We review the various genetic and environmental factors thought to be involved in PD, as well as the mechanisms that contribute to selective nigral cell death.

[1]  R. Duvoisin,et al.  Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats , 1985, Neuroscience Letters.

[2]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[3]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[4]  A. Cools,et al.  Neurorescuing effects of the GAPDH ligand CGP 3466B. , 2000, Journal of neural transmission. Supplementum.

[5]  K Teschke,et al.  Occupational and environmental risk factors for Parkinson's disease. , 2002, Parkinsonism & related disorders.

[6]  M Barinaga,et al.  Death by Dozens of Cuts , 1998, Science.

[7]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[8]  A. Barzilai,et al.  Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons — A possible novel pathogenetic mechanism in Parkinson's disease , 1994, Neuroscience Letters.

[9]  P. Vieregge,et al.  Long Term Exposure to Manganese in Rural Well Water Has No Neurological Effects , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  J. Labandeira-Garcia,et al.  Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants , 2000, Journal of neurochemistry.

[11]  S. Melov,et al.  Mitochondrial DNA mutations, oxidative stress, and aging , 2001, Mechanisms of Ageing and Development.

[12]  N. Volkow,et al.  Inhibition of monoamine oxidase B in the brains of smokers , 1996, Nature.

[13]  Strang Rr The etiology of Parkinson's disease. , 1970, Diseases of the nervous system.

[14]  H Checkoway,et al.  Dietary factors in Parkinson's disease: The role of food groups and specific foods , 1999, Movement disorders : official journal of the Movement Disorder Society.

[15]  I. Ceballos-Picot,et al.  Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. , 1998, Biochemical pharmacology.

[16]  Dallas W. Anderson,et al.  Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi , 1985, Neurology.

[17]  E. Zamrini,et al.  Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.

[18]  B. Müller-Myhsok,et al.  A susceptibility locus for Parkinson's disease maps to chromosome 2p13 , 1998, Nature Genetics.

[19]  G. Defazio,et al.  Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture , 1994, Brain Research.

[20]  J. Gorell,et al.  Environmental Risk Factors for Parkinson's Disease , 2003 .

[21]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[22]  Y. Agid Levodopa: Is toxicity a myth? , 1998, Neurology.

[23]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[24]  F. Cheng,et al.  Inhibitors of Mitochondrial Respiration, Iron (II), and Hydroxyl Radical Evoke Release and Extracellular Hydrolysis of Glutathione in Rat Striatum and Substantia Nigra , 1999, Journal of neurochemistry.

[25]  D. Calne,et al.  Evidence for environmental causation of Parkinson's disease. , 2002, Parkinsonism & related disorders.

[26]  A. Bentivoglio,et al.  Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.

[27]  P. Sonsalla,et al.  Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. , 1994, The Journal of pharmacology and experimental therapeutics.

[28]  V. Davila,et al.  Neurotrophic Effects of l‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte Cocultures , 1997, Journal of neurochemistry.

[29]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[30]  FRCPtt A. E. Harding,et al.  Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies , 1994, Annals of neurology.

[31]  C. Marsden,et al.  Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.

[32]  S. Kish,et al.  Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[33]  H. Yoshino,et al.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[34]  L. Fleming,et al.  Parkinson's disease and brain levels of organochlorine pesticides , 1994, Annals of neurology.

[35]  E. Hirsch,et al.  Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? , 1996, Neuroscience.

[36]  A. Schapira,et al.  Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects , 2000, The Lancet.

[37]  M. Yahr,et al.  Postencephalitic parkinsonism – a review , 1998, Journal of Neural Transmission.

[38]  B. Jenkins,et al.  Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[39]  O. Axelson,et al.  Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.

[40]  Y. Agid [Aging, disease and nerve cell death]. , 1995, Bulletin de l'Academie nationale de medecine.

[41]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[42]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Fishman,et al.  Prevention of vertebrate neuronal death by the crmA gene. , 1994, Science.

[44]  J. Gusella,et al.  Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes , 1994, Annals of neurology.

[45]  S. Dimauro,et al.  Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.

[46]  M. Nielsen,et al.  Caspase-mediated Parkin Cleavage in Apoptotic Cell Death* , 2002, The Journal of Biological Chemistry.

[47]  D. Schroeder,et al.  Amantadine treatment is an independent predictor of improved survival in Parkinson's disease , 1996, Neurology.

[48]  B. Shastry,et al.  Parkinson disease: etiology, pathogenesis and future of gene therapy , 2001, Neuroscience Research.

[49]  X M Cheng,et al.  A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. , 1993, Neuroepidemiology.

[50]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[51]  N. Hattori,et al.  An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. , 1994, Annals of Neurology.

[52]  C. Marsden,et al.  Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration , 2005, Journal of Neural Transmission.

[53]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[54]  J. Haines,et al.  Complete genomic screen in Parkinson disease: evidence for multiple genes. , 2001, JAMA.

[55]  R. Uitti,et al.  Geography, Drinking Water Chemistry, Pesticides and Herbicides and the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[56]  M. Chiba,et al.  Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control , 1997, Neurology.

[57]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[58]  C. Marsden,et al.  Mitochondrial respiratory chain function in multiple system atrophy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[59]  R. Uitti,et al.  Familial Parkinson's Disease: Possible Role of Environmental Factors , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[60]  M. Shelanski,et al.  Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Harvey Checkoway,et al.  Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. , 2002, American journal of epidemiology.

[62]  M Schulzer,et al.  A mathematical model of pathogenesis in idiopathic parkinsonism. , 1994, Brain : a journal of neurology.

[63]  Paola Piccini,et al.  The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.

[64]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[65]  K. Marder,et al.  Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations , 2002, Neurology.

[66]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[67]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[68]  H. Kimura,et al.  Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.

[69]  B. Ritz,et al.  Parkinson's disease mortality and pesticide exposure in California 1984-1994. , 2000, International journal of epidemiology.

[70]  A. Benabid,et al.  Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies , 1996, The European journal of neuroscience.

[71]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[72]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[73]  L. Olson,et al.  Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  H. Przuntek,et al.  Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued , 2005, European Journal of Clinical Pharmacology.

[75]  D. Morens,et al.  Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. , 1994, American journal of epidemiology.

[76]  S. Lipton,et al.  Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[77]  S. Melov,et al.  Mitochondrial Oxidative Stress: Physiologic Consequences and Potential for a Role in Aging , 2000, Annals of the New York Academy of Sciences.

[78]  J. H. Li,et al.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Zivadinov,et al.  Familial and environmental risk factors in Parkinson's disease: a case–control study in north‐east Italy , 2002, Acta neurologica Scandinavica.

[80]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[81]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[82]  A. Rajput,et al.  Frequency and Cause of Parkinson’s Disease , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[83]  H. Chertkow,et al.  Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. , 1995, Archives of neurology.

[84]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[85]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[86]  G. Román,et al.  Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.

[87]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[88]  A. J. Bradbury,et al.  1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway , 1986, Nature.

[89]  C. Tanner,et al.  Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease , 1998, Neurology.

[90]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[91]  J. Riggs,et al.  Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. , 1992, Clinical neuropharmacology.

[92]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[93]  Z. Speiser,et al.  Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. , 1998, Journal of neural transmission. Supplementum.

[94]  S. Gruber,et al.  The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. , 1991 .

[95]  W. Weiner Parkinson’s Disease and Movement Disorders , 2000, Current Clinical Practice.

[96]  D. Perl,et al.  A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.

[97]  Jeffery K. Taubenberger,et al.  Initial Genetic Characterization of the 1918 “Spanish” Influenza Virus , 1997, Science.

[98]  E. Hirsch,et al.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[99]  H. Forman,et al.  Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity , 2000, The Journal of Biological Chemistry.

[100]  B. Davidson,et al.  Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.

[101]  N. Wood,et al.  Genetics of Parkinsonism: a review , 2001, Annals of human genetics.

[102]  Y. Agid,et al.  Genetic complexity and Parkinson's disease. , 1997, Science.

[103]  Y. Agid,et al.  Adverse reactions to levodopa: drug toxicity or progression of disease? , 1998, The Lancet.

[104]  E. Tolosa,et al.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.

[105]  Y. Yang,et al.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. , 2000, Neuroscience.

[106]  Y. Mizuno,et al.  Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.

[107]  V. Dawson Neurobiology. Of flies and mice. , 2000, Science.

[108]  R. Godwin-Austen,et al.  Smoking and Parkinson's disease. , 1982, Journal of neurology, neurosurgery, and psychiatry.

[109]  J. Hubble,et al.  Risk factors for Parkinson's disease , 1993, Neurology.

[110]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  B J Hoffer,et al.  Dopamine neuron agenesis in Nurr1-deficient mice. , 1997, Science.

[112]  R. Kalaria,et al.  Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[113]  P. Maher,et al.  A Role for 12-lipoxygenase in Nerve Cell Death Caused by Glutathione Depletion , 1997, Neuron.

[114]  A. Rajput The protective role of levodopa in the human substantia nigra. , 2001, Advances in neurology.

[115]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[116]  S. Khuder,et al.  A meta-analysis of Parkinson's disease and exposure to pesticides. , 2000, Neurotoxicology.

[117]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[118]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[119]  M. Beal,et al.  Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease , 2001, The Journal of Neuroscience.

[120]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[121]  A. Lees,et al.  Late Progression of Post-Encephalitic Parkinson's Syndrome , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[122]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[123]  R. G. Lee,et al.  Parkinson's disease , 1993, Neurology.

[124]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[125]  H P Ludin,et al.  Parkinson's disease in twins , 1992, Neurology.

[126]  R. Mayeux,et al.  Smoking and Parkinson’s disease in twins , 2002, Neurology.

[127]  D. Calne,et al.  Occupational risk factors in Parkinson's disease. , 1999, Canadian journal of public health = Revue canadienne de sante publique.

[128]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[129]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[130]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[131]  E. Teng,et al.  A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. , 1996, Archives of neurology.

[132]  J. Nutt,et al.  Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. , 2002, Archives of neurology.

[133]  M Schulzer,et al.  Clinical observations on the rate of progression of idiopathic parkinsonism. , 1994, Brain : a journal of neurology.

[134]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[135]  G. Donnan,et al.  Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice , 1987, Brain Research.

[136]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[137]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[138]  K. Jellinger Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.

[139]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[140]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[141]  K. Jellinger,et al.  The enigma of cell death in neurodegenerative disorders. , 2000, Journal of neural transmission. Supplementum.

[142]  M. Yen,et al.  Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan County, Taiwan , 2001 .

[143]  C. Tzourio,et al.  Familial aggregation of Parkinson’s disease , 1999, Neurology.

[144]  A. McMahon,et al.  Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein , 1995, Nature Medicine.

[145]  D B Calne,et al.  Is idiopathic parkinsonism the consequence of an event or a process? , 1994, Neurology.

[146]  Annette M. Schmid,et al.  Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.

[147]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[148]  M. Goedert,et al.  Tau and Parkinson disease. , 2001, JAMA.

[149]  Temple F. Smith,et al.  Survey of human mitochondrial diseases using new genomic/proteomic tools , 2001, Genome Biology.

[150]  A A Hicks,et al.  Familial aggregation of Parkinson's disease in Iceland. , 2000, The New England journal of medicine.

[151]  Y. Agid,et al.  Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions , 1998, Annals of neurology.

[152]  J. Nutt,et al.  Increased risk of Parkinson's disease in parents and siblings of patients , 1994, Annals of neurology.

[153]  J. Kurth,et al.  Association of a monoamine oxidase B allele with Parkinson's disease , 1993, Annals of neurology.

[154]  R. Uitti,et al.  Timely levodopa (LD) administration prolongs survival in Parkinson's disease. , 1997, Parkinsonism & related disorders.

[155]  O. Isacson,et al.  Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.

[156]  J. Chen,et al.  Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. , 1994, Progress in brain research.

[157]  A. Blackburn,et al.  Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.

[158]  M. Graeber,et al.  On the question of apoptosis in the parkinsonian substantia nigra , 1997, Acta Neuropathologica.

[159]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[160]  Shelley R. Winn,et al.  Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.

[161]  Dr Ira Shoulson Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa , 1996, Annals of neurology.

[162]  F. Vaglini,et al.  Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors , 1998, Journal of neurochemistry.

[163]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[164]  P C O'Brien,et al.  Brain injury and neurologic sequelae , 1991, Neurology.

[165]  Of Flies and Mice , 2000, Science.

[166]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[167]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[168]  G. Barja,et al.  Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. , 2002, Toxicology.

[169]  C. C. Johnson,et al.  Adult nutrient intake as a risk factor for Parkinson's disease. , 1999, International journal of epidemiology.

[170]  H. Petrovitch,et al.  Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease , 2001, Drugs & aging.

[171]  D. Calne The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.

[172]  J. Nutt,et al.  Environmental antecedents of young‐onset Parkinson's disease , 1993, Neurology.

[173]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[174]  M Schulzer,et al.  The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic , 1992, Annals of neurology.

[175]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[176]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[177]  A. E. Harding,et al.  Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography , 1992, Neurology.

[178]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.

[179]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[180]  M. Mouradian Recent advances in the genetics and pathogenesis of Parkinson disease , 2002, Neurology.

[181]  J. Mankovich,et al.  Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. , 1995, Science.

[182]  M. Naoi,et al.  Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. , 2000, Journal of neural transmission. Supplementum.

[183]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[184]  M. Farrer,et al.  A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. , 1999, Human molecular genetics.

[185]  M. Quik,et al.  Nicotinic receptors and Parkinson's disease. , 2000, European journal of pharmacology.

[186]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[187]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[188]  C. Ward,et al.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.

[189]  David R. Cox,et al.  A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation , 1995, Nature Genetics.

[190]  A. Stoessl,et al.  Etiology of Parkinson's Disease , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[191]  J. Milbrandt,et al.  Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.

[192]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[193]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[194]  S. Shimohama,et al.  Methylphenylpyridium ion enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon , 1994 .

[195]  Gregory G. Brown,et al.  Occupational exposures to metals as risk factors for Parkinson's disease , 1997, Neurology.

[196]  M. Naoi,et al.  An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.

[197]  D. Morens,et al.  Cigarette smoking and protection from Parkinson's disease , 1995, Neurology.

[198]  J. Houwing-Duistermaat,et al.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. , 2001, American journal of human genetics.

[199]  W. Tatton,et al.  (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. , 1996, Journal of neural transmission. Supplementum.

[200]  高橋 均,et al.  Familial juvenile parkinsonism: clinical and pathologic study in afamily , 1993 .

[201]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[202]  H. Przuntek,et al.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. , 1991, European journal of pharmacology.

[203]  L. Barbeito,et al.  Peroxynitrite‐Induced Cytotoxicity in PC12 Cells: Evidence for an Apoptotic Mechanism Differentially Modulated by Neurotrophic Factors , 1995, Journal of neurochemistry.

[204]  V. Hachinski,et al.  Environmental Exposures in Elderly Canadians With Parkinson’s Disease , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[205]  H. Okada,et al.  The substantia nigra is a major target for neurovirulent influenza A virus , 1995, The Journal of experimental medicine.

[206]  L. Olson,et al.  Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse , 1985, Journal of neurochemistry.

[207]  A Hartley,et al.  Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.

[208]  J. Cooper,et al.  Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.

[209]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[210]  Y. Mizuno,et al.  bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.

[211]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[212]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.

[213]  M. Druet‐Cabanac,et al.  Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. , 2000, Neuroepidemiology.

[214]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[215]  E. Love,et al.  Effects of agricultural work and other proxy-derived case-control data on Parkinson's disease risk estimates. , 1995, American journal of epidemiology.

[216]  A. Rajput,et al.  Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[217]  Raúl de la Fuente‐Fernández Maternal effect on Parkinson's disease , 2000, Annals of neurology.

[218]  C. Tanner,et al.  Environmental Factors in the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[219]  B. Snow,et al.  Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations. , 1995, Parkinsonism & related disorders.

[220]  R. Oppenheim,et al.  Peptide inhibitors of the ice protease family arrest programmed cell death of motoneurons in vivo and in vitro , 1995, Neuron.

[221]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.